Our Leadership
Proteomics International has an unparalleled scientific and commercial team from a diverse range of backgrounds. The team is highly skilled in all aspects of protein chemistry, encompassing the cutting edge of mass spectrometry to traditional methods, product development, and commercialisation.
David Morris, Chief Executive Officer (CEO) and Managing Director (MD)
David is a global healthcare and medical technology executive with extensive experience spanning medical devices and life sciences. His career includes executive leadership roles at Cochlear, Nanosonics, Polynovo and Monash IVF, where he has proven track record in commercial growth, international market expansion, successful product commercialisation and building high-performing teams. He brings deep expertise in strategy development, regulatory pathways, global market entry and market development across the Americas, Europe and Asia. His appointment reflects the Company’s sharpened focus on commercial execution and global market penetration for the Promarker® diagnostic pipeline.
Qualifications:
His academic background includes degrees in Business and Applied Science from Monash University and executive education from Northwestern University's Kellogg School of Management. He is also a graduate of the Australian Institute of Company Directors.
Phillip Prather, Chief Commercial Officer
As the Chief Commercial Officer for Proteomics International, Phillip is responsible for Global Sales, Marketing, and Customer Engagement activities. Phillip brings extensive leadership in the medical devices industry, particularly developing new global markets and successfully launching products for innovative Australian and International companies including Cochlear, QIAGEN, Cellestis, PHILIPS, Medtronic, and Nano-X (now Leo Cancer Care).
Qualifications
Graduate, Australian Institute of Company Directors (AICD)
Master of Commerce (Marketing), University of New South Wales
GradDip Finance, Case Western Reserve University
Bachelor degrees, Biology (Honours in Neurobiology, College of Medicine) and Economics, University of Vermont
Dr Scott Bringans, Head of Research
Scott is responsible for all Research areas within Proteomics International. This involves oversight of Biomarker discovery and development projects encompassing PromarkerD, PI’s predictive test for diabetic nephropathy. Alongside the biomarker research program is the development and implementation of novel methods for examining biological systems (particularly venoms) for discovery of novel therapeutic peptides where genomic/ proteomic information is unavailable or incomplete. He also leads the development of new chromatographic and mass spectrometric methods for handling of complex biological samples for analysis and investigation.
Scott has a commercial background as proteomics scientist and mass spectrometry specialist at a New Zealand based R&D company, now part of AgResearch. This was preceded by a Post-Doctoral Fellowship at the National Cancer Institute, USA, looking at bioactive protein isolation, purification and identification of both anti-cancer and anti-HIV leads from marine sources. Scott’s skills are wide ranging and include expertise with mass spectrometers, liquid chromatography, assay development and bioinformatic analysis.
Qualifications
PhD, Department of Chemistry, University of Canterbury
BSc (Hons), Department of Chemistry, University of Canterbury
Dr Johan Conradie, Clinical Pathologist
Johan is a Chemical Pathologist with over 21 years of experience in clinical biochemistry and toxicology, spanning both South Africa and Australia. He began his career after completing an Bachelor of Medicine and Surgery (MBChB) at the University of Pretoria in 1998 and specialised in Chemical Pathology at the University of Witwatersrand, earning his FCPath (Chem) in 2005. He gained his FRCPA in 2008 and later completed an MBA at the University of Western Australia in 2019.
At Proteomics International, Johan supports the Company’s accreditation processes, ensuring compliance with ISO 15189 and contributing to innovative diagnostics that improve patient outcomes. His professional interests include computational and digital pathology, toxicology, and advancing laboratory standards to align with global best practices.
In addition to his work at Proteomics International, Johan serves as the Medical Director of Western Diagnostic Pathology and holds an Adjunct Associate Professorship at the University of Notre Dame Fremantle. He is actively involved in teaching, conducting technical assessments for NATA, and serving as an examiner for the Royal College of Pathologists of Australasia (RCPA). Johan has delivered numerous presentations and contributed to academic publications on topics such as diagnostic trends, endocrinology, and AI in pathology.
Qualifications
2019 Master of Business Administration, UWA, Australia
2008 FRCPA, Royal College of Pathologists of Australasia
2005 FCPath(Chem), University of Witwatersrand, South Africa
1998 Bachelor of Medicine and Surgery (MBChB), University of Pretoria, South Africa
Dr Kirsten Peters, Head of Clinical Studies
Kirsten has over 15 years of experience in clinical and genetic epidemiology. Kirsten leads the clinical studies and biostatistics team at Proteomics International, responsible for the development and validation of Promarker®D and diagnostics in the Promarker™ pipeline. She has been with the company for over 10 years and has been a Consultant at the University of Western Australia for 15 years. Kirsten has extensive experience in data analysis and has co-authored over 40 peer-reviewed journal articles.
Qualifications
PhD (Research), Medical Sciences, JCSMR, ANU, Australia
BSc with honours in Medical Sciences, UON, Australia
BSc in Molecular Biology and Medical Sciences, UON, Australia